Dr. John Cush RheumNow
5 years 8 months ago
After your 2 doses of COVID vaccine, YES you need to continue to wear a mask, cont. hand washing & social distancing - so as to continue to protect yourself and others. While vaccinated you can still become infected and spread infection. https://t.co/TkcSNx0hF1
A novel report from PNAS suggests that in osteoarthritis (OA), the damage is not entirely from body weight and mechanics, instead it may be from adipose tissue itself.
Dr. John Cush RheumNow
5 years 8 months ago
A oatint infected with COVID-19- Yes they should get vaccinated ~90days after infection has resolved.Antibody testing is not needed before you are vaccinated. Evidence suggests that reinfection is uncommon in the 90 days after initial infection. https://t.co/TkcSNx0hF1.
Dr. John Cush RheumNow
5 years 8 months ago
Preprint results of the REMAP-CAP trial in the UK shows that IL-6 inhibitors, when given within 24 hrs of ICU entry for COVID-19, lowers mortality rate by 36%. Hosp mortality in 353 TCZ was 28%, 48 sarilumab was 22% in 402 controls was 36%. https://t.co/fkjOz99t0l
Dr. John Cush RheumNow
5 years 8 months ago
ACR Convergence 2020 Late Breaking Abstracts available from the ACR "Spotlight" slide give away. 10 slides on COVID, Tyk2 in PsA, FAST febuxostat study, Tofa in AS and novel drugs for SLE and PSS https://t.co/DvcDyusCUR
UK Clinical Practice Research Datalink population study shows that patients with immune-mediated inflammatory diseases, such as RA, PMR, GCA and IBD, have an augmented risk of CV outcomes with glucocorticoid use; even lower doses had a near doubling of their underlying CVD risk.
Dr. John Cush RheumNow
5 years 8 months ago
RheumNow Podcast is up! Benlysta safety, HCQ lowers thromboses, HCQ adherence, Telemedicine, Actemra in COVID,, 2021 looking forward and zoomatology! Watch it here>> https://t.co/PtfEUPB1hc or listen to podcast on Apple> https://t.co/FHJv01AAbC or Android>https://t.co/Iylluqqeej
Dr. John Cush RheumNow
5 years 8 months ago
ACR Convergence 2020 Fireside Chats – Top presentations in nr-axSpA, AS, axial PsA
Sponsored by Novartis Medical Affairs
Unable to attend all the key sessions at #ACR20? Listen to the experts as they present their views on the top abstracts.
https://t.co/r5Cf4WS63s https://t.co/N6QYsofbWe
Dr. John Cush RheumNow
5 years 8 months ago
Our latest podcast is up—Lights, Camera, Zoom. We review the news, journal articles and blogs featured on RheumNow this week. Download wherever podcasts are available.
https://t.co/8O5AWNa88d
Dr. John Cush RheumNow
5 years 8 months ago
Rheumatologists: Record your question or case for the RheumNow podcast.
https://t.co/NDhYNX50e2
Dr. John Cush RheumNow
5 years 8 months ago
Adherence to Hydroxychloroquine Lowers Lupus Mortality
A lupus cohort study from British Columbia, Canada has shown that medication adherence with hydroxychloroquine (HCQ) is associated with a 71% to 83% lower mortality.
Read more...
https://t.co/luoot7sZZl https://t.co/i2qrqU4EDy
Dr. John Cush RheumNow
5 years 8 months ago
ACR Convergence 2020 Fireside Chats – top presentations in Still’s disease
Sponsored by Novartis Medical Affairs
Unable to attend all the key sessions at ACR Convergence 2020? Listen to the experts as they present their views on the top abstracts.
https://t.co/MD6lU5oIvy https://t.co/wGVUI5Xjkk
Dr. John Cush RheumNow
5 years 9 months ago
ACR Convergence 2020 Fireside Chats- top presentations in nr-axSpA, AS, axial PsA and Still’s disease.
Sponsored by Novartis Medical Affairs
Unable to attend the key sessions at #ACR20? Listen to the experts as they weigh in on the top abstracts.
https://t.co/bFrbEGtnw3 https://t.co/dMqhX0f6te
The fate of the Trump administration's "most favored nation" (MFN) rule for bringing down prescription drug prices remains uncertain as President-elect Joe Biden prepares to assume office later this month.
